Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 30;21(1):89.
doi: 10.1186/s43141-023-00544-3.

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR

Al-Shazly Gaber Mohamed Galal  1 , Reham M Dawood  2 , Mostafa K El Awady  2 , Yasser Mohamed Mohamed El-Dessouky  3 , Mohamed Mahmoud Abdel-Halim Mahmoud  3 , Mohamed Darwish Ahmed Abd Alla  4
Affiliations

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR

Al-Shazly Gaber Mohamed Galal et al. J Genet Eng Biotechnol. .

Abstract

Background and aims: Predictors of chronic HCV response to oral antiviral therapy (OAT) are related to host genetic variations. Single nucleotide polymorphisms (SNP) and alleles variations of host genes in association with hepatic fibro-cirrhotic changes have a distinct role in OAT outcomes. The current research evaluated the association of Cirrhosis-Risk-Scores (CRS) values, based on the correlation of seven genes signature-SNPs, with sonographic liver parenchymal changes in determining OAT outcomes.

Methods: All study subjects (n = 54) were recruited three months after completing OAT and classified into three groups. Group I (n = 21) had negative HCV PCR, group II (n = 17) showed positive solitary intra-PBMCs HCV infection, and group III(n = 16) was serum HCV RNA PCR-positive. All study-population were subjected to examination by hepatic-ultrasound (US), FIB-4-scoring, and screening for 7 gene-signature that addressed CRS values as low, intermediate, and high depending on gene SNPs identification.

Results: Group I showed a significant association with low CRS values compared to other groups (P < 0.001). Solitary intra- PBMCs HCV infection in group II was significantly combined with intermediate CRS values in comparison to groups I and III (P < 0.001). The high CRS values were significantly found in group III when compared to groups I and II (P < 0.01). On US imaging, low CRS values were common in normally appeared hepatic parenchyma (P < 0.001) and high CRS values were frequent in coarse-liver (P < 0.001), while bright-liver-tissues appearance was mainly detected in the intermediate CRS category (P = 0.09). On FIB-4 scoring, high CRS value were associated with hepatic fibro-cirrhosis compared to intermediate (P < 0.001) and low (P = 0.08) CRS-categories.

Conclusion: The current study concluded the association of (a) high CRS values with coarse liver in viral-RNA serologic relapse, (b) low CRS values with normal liver tissues in sustained virologic response (SVR), (c) intermediate CRS values with bright liver in solitary PBMCs relapse.

Keywords: CRS; DAAs; HCV Relapse; Liver fibro-cirrhosis; PBMCs PCR.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest related to this research. All procedures performed in the current work that involved human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the current study. This article does not contain any studies with animals performed by any of the authors. Ethical approval certificate Registration number: Trop.Med._17Med.Research_Inf.GIT.Liv.Dis._0000017.

All authors declare that they have no competing interests.

Similar articles

See all similar articles

References

    1. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: Relationship with gender and viral genotype. J Clin Immunol. 2011;31:891–899. doi: 10.1007/s10875-011-9547-1. - DOI - PubMed
    1. Marabita F, Aghemo A, de Nicola S, Rumi MG, Cheroni C, Scavelli R, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54:1127–1134. doi: 10.1002/hep.24503. - DOI - PubMed
    1. Papastergiou V. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015;3:210. 10.12998/wjcc.v3.i3.210 - PMC - PubMed
    1. Coppola N. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015;3:807. 10.12998/wjcc.v3.i9.807 - PMC - PubMed
    1. ABD ALLA MDA, EL-DESSOUKY YMM, ABDEL-HAMID MR, ZAIN EL-DEEN ANA. Prevalence of HCV infection among health care employee at Al Azhar University hospitals in Cairo, Egypt. J Egypt Soc Parasitol 2017;47:459–66. 10.21608/jesp.2017.77516

LinkOut - more resources